順天堂大学医学部附属順天堂医院 がん治療センターセンター長・化学療法室室長、順天堂大学医学部附属順天堂医院 腫瘍内科 科長、順天堂大学大学院医学研究科 臨床腫瘍学 教授
日本内科学会 認定医 日本臨床腫瘍学会 がん薬物療法専門医・指導医 日本がん治療認定医機構 がん治療認定医
固形がん（主に消化器がん、軟部肉腫、乳がん、原発不明がんなど）に対する薬物療法を専門としている。また、遺伝子解析に基づく個別化医療を実現するべく、がんゲノム医療を早期から導入し臨床への応用を目指している。
1992年
東北大学 医学部
卒業
1996年
東北大学大学院 医学研究科
博士課程 修了 医学博士取得
2000年
東北大学加齢医学研究所附属病院
助手（化学療法科）
2007年
東北大学病院
講師
2009年
東北大学 加齢医学研究所 癌化学療法研究分野
准教授
2013年
順天堂大学大学院 医学研究科臨床腫瘍学
教授
1. Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Diagnostics (Basel) 11(2).
Kato, S. (2021).
2. A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma. Sci Rep 10(1): 6214.
Takakuwa, K., et al. (2020).
3. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int J Clin Oncol 25(3): 403-417.
Naito, Y., et al. (2020).
4. Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. Jpn J Clin Oncol 49(2): 174-182.
Kato, S., et al. (2019).
5. Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer. Oncotarget 9(18): 14193-14206.
Yamaguchi, S., et al. (2018).
6. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open 1(2): e000037.
Shibata, H., et al. (2016).
7. High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H. Oncol Rep 31(3): 1043-1050.
Imai, H., et al. (2014).
8. Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients. Oncology 83(2): 101-107.
Kato, S., et al. (2012).
9. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28(6): 622-629.
Petitjean, A., et al. (2007).
10. The UMD TP53 database and website: update and revisions. Hum Mutat 27(1): 14-20.
Hamroun, D., et al. (2006).
11. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 17(5): 842-847.
Iacopetta, B., et al. (2006).
12. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12(4): 1157-1167.
Olivier, M., et al. (2006).
13. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34(5): 1317-1325.
Mathe, E., et al. (2006).
14. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12(1): 62-69.
Soussi, T., et al. (2006).
15. Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations. Hum Mutat 27(2): 163-172.
Mathe, E., et al. (2006).
16. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 25(1): 6-17.
Soussi, T., et al. (2005).
17. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 65(6): 2108-2114.
Kakudo, Y., et al. (2005).
18. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 24(46): 6976-6981.
Kawaguchi, T., et al. (2005).
19. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279(1): 348-355.
Shiraishi, K., et al. (2004).
20. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100(14): 8424-8429.
Kato, S., et al. (2003).
21. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 60(12): 3147-3151.
Han, S. Y., et al. (2000).
22. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 59(12): 2781-2786.
Shimada, A., et al. (1999).
23. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer. Oncogene 18(25): 3761-3765.
Sunahara, M., et al. (1999).
24. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters. Cancer Res 59(23): 5908-5911.
Kato, S., et al. (1999).
25. Differentiation-dependent enhanced expression of protein phosphatase 2Cbeta in germ cells of mouse seminiferous tubules. FEBS Lett 396(2-3): 293-297.
Kato, S., et al. (1996).
本ページにおける情報は、医師本人の申告に基づいて掲載しております。内容については弊社においても可能な限り配慮しておりますが、最新の情報については公開情報等をご確認いただき、またご自身でお問い合わせいただきますようお願いします。
なお、弊社はいかなる場合にも、掲載された情報の誤り、不正確等にもとづく損害に対して責任を負わないものとします。